“It is worth remembering that injudicious use of PSA test, and the downstream consequences of overtreatment and complications, can obscure the benefits associated with PSA-based early detection of prostate cancer,” writes Badar M. Mian, MD.
“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for…
“We are very excited here at Potomac Urology to be the first center in the United States, and just the second center internationally, to offer…
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,”…
“A key piece of the guideline is that we need to offer radiation at a PSA of 0.5 ng/mL or lower and maybe even, for…
Take this survey powered by surveymonkey.com. Create your own surveys for free.
“In terms of the minimal overlapping toxicity, our non-clinical data from the xenograft model showed minimal toxicity with the combination,” says Caroline Foxton, PhD.
“What we found is that over a third of patients, 36%, had positive family history of either prostate, breast, or pancreatic cancer. And if you…
“Our clinical trial is the first to show a longer time to biochemical recurrence with chemotherapy plus standard hormone therapy for patients with locally advanced,…
iTind is a temporary nitinol device used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia.
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.
